Skip to content

Ginkgo Bioworks DNA Concentration Risk %

Concentration Risk % at other companies

Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
93.1%-5.3pp
Heartland Express logo
Heartland ExpressHTLD
32%+6.0pp
Enovix Corporation logo
Enovix CorporationENVX
83%+36.0pp
Weis Markets logo
Weis MarketsWMK
100%0.0pp
Innoviva, Inc. logo
Innoviva, Inc.INVA
36%+7.0pp
Strattec Security logo
Strattec SecuritySTRT
0.5%0.0pp

Segments

By product

See full
Pharmaceutical and biotechnology38%
Government and defense35%+119%
Agriculture13%-68.3%
Food and nutrition7%+75.0%
Industrial and environment7%0.0%
Consumer and technology0%-100%

By segment

See full
Cell Engineering15%-25.0%
Biosecurity12%-25.0%

By geography

See full
UNITED STATES66%-18.5%
DENMARK13%+18.2%

Other financials

Income statement

See full
Revenue$19.5M-49.1%
Gross profit$16.4M-52.0%
Operating income-$71.4M+11.9%
Net income-$82.6M+9.2%
EPS (diluted)-$1.42+27.6%

Balance sheet

See full
Cash & equivalents$188.7M-46.9%
Total debt$410.7M-5.5%
Total equity$443.2M-31.6%
Total assets$1.0B-20.1%

Cash flow

See full
Operating cash flow-$46.7M+9.4%
CapEx$1.9M-74.6%
Free cash flow-$48.6M+17.8%

Valuation

See full
Market cap$625.16M+24.6%
Enterprise value$847.19M+45.9%
P/S4.4×+2.2×

Profitability

See full
Operating margin-210.7%+7.6pp
Net margin-215.4%+8.3pp
FCF margin-119%-21.2pp

Returns & leverage

See full
Return on equity-55.8%-1.8pp
Debt / equity0.9×+0.3×
Current ratio5.2×+0.3×